SAN ANTONIO - Monday, September 30th 2013 [ME NewsWire]
(BUSINESS
WIRE) The Board of Directors of the parent company of Kinetic Concepts,
Inc. (KCI) and LifeCell Corporation (LifeCell) announced today that
KCI, LifeCell and Systagenix will form one globally diversified wound
care, biologics and regenerative medicine company under the leadership
of President & CEO Joe Woody. Phil Croxford, the current commercial
operations leader at LifeCell, has been appointed Senior Vice President
and the permanent leader of LifeCell.
The
combined company will be the global leader in transformational healing
solutions, devoted to advancing the science of healing with superior
products, innovative therapies and cost effective solutions that speed
healing, reduce complications and improve patient lives. Each of the
businesses will execute on this unified vision by leveraging shared
competencies, portfolio expertise and existing sales channels.
As
one of the top global medical technology companies, the combined
company will remain the undisputed leader in negative pressure wound
therapy, the number one provider of regenerative tissue products used
for breast reconstruction and hernia repair and a market leader in
advanced wound care. KCI, LifeCell and Systagenix will be poised for
future success as a strategically diversified global company, with
established commercial scale and a world-class wound care and biologics
portfolio.
“The
combination of these businesses will form a leading medical technology
company with over $2 billion in revenue and a very important position
within the healthcare system,” said Buddy Gumina, chairman of the Board
of Directors of the parent company of KCI and LifeCell. “The new
company, under the proven leadership of Joe Woody, will amplify existing
capabilities, open the door for new growth opportunities and improve
the lives of patients around the world.”
“Operating
as one company will foster collaboration and increased innovation
across platforms, leading to exciting new products that will address
unmet clinical needs,” said Joe Woody, president & CEO. “The
combination of KCI, LifeCell and Systagenix will allow us to strengthen
our customer relationships, while creating opportunities to cross-sell
our products across the entire continuum of care – following the patient
from the operating room to the home with a combined portfolio of
best-in-class products and therapies.”
KCI
and LifeCell will begin operating as one company immediately under the
leadership of President & CEO Joe Woody. Systagenix will be
integrated into the combined company upon closing of KCI’s acquisition
of Systagenix, which is expected to occur in the fourth quarter of 2013.
About KCI
KCI
is a leading global medical technology company devoted to
understanding, developing and commercializing innovative,
high-technology transformational healing solutions for customers and
patients in more than 65 countries around the world. Headquartered in
San Antonio, Texas, KCI is committed to advancing the science of healing
and positively impacting patient care by developing customer-driven
innovations to meet the evolving needs of healthcare professionals.
Proprietary KCI negative pressure technologies have revolutionized the
way in which caregivers treat a wide variety of wound types. The V.A.C.®
Therapy System has been used on more than 7 million wounds worldwide.
Additional information about KCI and its products is available at
www.KCI1.com.
About LifeCell
LifeCell
Corporation, based in Bridgewater, NJ, is a leader in regenerative
medicine, develops and markets innovative tissue repair products for the
reconstructive, orthopedic and urogynecologic biosurgery markets.
LifeCell™ products include Strattice™ Reconstructive Tissue Matrix and
AlloDerm® Regenerative Tissue Matrix for plastic, reconstructive, and
general surgical applications; Cymetra® Regenerative Tissue Matrix, a
particulate form of AlloDerm® Tissue Matrix suitable for injection;
Repliform® Regenerative Tissue Matrix for urogynecologic surgical
procedures; Graftjacket® and Conexa™ for orthopedic surgical procedures;
and the SPY® Elite System for the visualization and evaluation of
tissue perfusion. Additional information about LifeCell and its products
is available at www.LifeCell.com.
About Systagenix
Systagenix
is a global leader in innovative wound care established in 2008
following the acquisition of Johnson & Johnson’s professional wound
care business by One Equity Partners. Systagenix is 100% dedicated to
wound care, developing and marketing advanced wound diagnostic and
therapeutic solutions and supplying over 20 million advanced wound
dressings per month globally. Systagenix’ longstanding commitment to
skin and wound care began with innovative wound care treatments
developed by the experienced team of R&D Scientists at the Gargrave
Centre of Excellence for Wound Healing in North Yorkshire, England. With
approximately 800 employees worldwide, Systagenix distributes products
and services to more than 100 countries.
Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20130930005524/en/
Contacts
KCI Corporate Communications
Mike Barger, +1-210-255-6824
mike.barger@kci1.com
KCI Investor Relations
Nathan Speicher, +1-210-255-6027
nathan.speicher@kci1.com
Permalink: http://www.me-newswire.net/news/8656/en
No comments:
Post a Comment